Home › Psychology

📖 3 min read

Mycosis fungoides and Sézary syndrome: first US guidelines on allogeneic stem cell transplant

The key finding

A panel of 32 specialists across dermatology, hematology, oncology, and radiation therapy reached consensus on 16 clinical recommendations for allogeneic stem cell transplant in mycosis fungoides (MF) and Sézary syndrome (SS). This marks the first published guidance in the United States on referral criteria, timing, and transplant procedures for these rare cutaneous T-cell lymphomas. At least 75% agreement among experts was required for each statement to achieve consensus. The recommendations address a critical gap: while allogeneic hematopoietic cell transplant (allo-HCT) is recognized as the only potentially curative option for MF/SS and appears in national treatment guidelines, clinicians have lacked specific direction on how and when to use it.

What the study looked like

Researchers conducted a Delphi survey—a structured method for building expert consensus—among 32 U.S.-based specialists. The panel included nine dermatologists, ten transplant hematologists/oncologists, eight non-transplant hematologists/oncologists, and five radiation oncologists. Participants reviewed evidence and voted on proposed clinical practice statements across multiple rounds until reaching agreement thresholds. To qualify as consensus, at least 75% of the panel had to agree on a given recommendation. The survey covered four major domains: when to refer patients for transplant consideration, which preparative regimens and procedures to use, what disease status is acceptable at transplant, and how to coordinate multidisciplinary care before and after the procedure. This collaborative approach ensured that perspectives from skin specialists, cancer doctors, and transplant experts were all represented.

Why researchers think this happened

Mycosis fungoides typically progresses slowly, but a subset of patients develop aggressive or treatment-resistant disease. Sézary syndrome is inherently aggressive, causing severe immune compromise that leads to life-threatening infections and high mortality. Until this initiative, clinicians managing these patients faced a void: national guidelines acknowledged allo-HCT as potentially curative, yet no detailed roadmap existed for selecting candidates, timing the transplant, or coordinating the complex pre- and post-transplant care these patients require. The researchers convened a multidisciplinary panel because MF/SS care spans dermatology (skin manifestations), hematology/oncology (systemic lymphoma management), and transplant medicine (curative procedure). By synthesizing expertise across these fields, the panel aimed to translate scattered clinical experience into actionable, consensus-based guidance that could improve outcomes and standardize care.

How to read this carefully

These are expert consensus recommendations, not findings from a randomized controlled trial. The statements reflect the collective judgment of 32 specialists based on available evidence and clinical experience, but they have not been tested prospectively in a large patient cohort. MF and SS are rare diseases, so high-quality trial data are limited. Consensus thresholds (75% agreement) ensure broad support, but some recommendations may evolve as new evidence emerges. The panel itself highlights areas requiring future investigation, acknowledging uncertainty in the field. Additionally, consensus guidelines provide a framework, not rigid rules; individual patient factors—age, comorbidities, prior treatments—will influence real-world transplant decisions. Readers should view these as expert-informed starting points rather than guarantees of outcomes.

What this means for everyday life

If you or a loved one has been diagnosed with mycosis fungoides or Sézary syndrome, these new guidelines offer important clarity. Patients with progressive or treatment-resistant disease now have a clearer pathway: dermatologists and oncologists can consult specific criteria to determine when a stem cell transplant referral is appropriate. This may lead to earlier, more coordinated discussions about transplant candidacy, potentially improving access to the only curative option currently available. For clinicians, the recommendations reduce uncertainty and variation in care, which could mean more consistent treatment quality across centers. While stem cell transplant carries significant risks and is not suitable for everyone, having a structured, multidisciplinary framework helps ensure that the right patients are identified at the right time—an important step forward for a rare disease where every treatment decision matters.


Source

  • PMID: 40199382 (read full paper on PubMed)
  • Journal: Journal of the American Academy of Dermatology (2025)

Articles on this site are adapted from PubMed abstracts as general-interest explainers. They are not intended as medical advice.

📝 This article was adapted by the PubMed Trivia editorial team using Claude (Anthropic) as an adaptation assistant, based on the PubMed abstract cited above. Our editorial workflow includes automated NG-term checks (medical-claims law), careful "correlation vs causation" distinction, and mandatory PMID + source URL disclosure. See the full pipeline on our editorial policy and editor pages. Please report errors to sciencepubmedjp@gmail.com (we respond within 48 hours).